MKI67 and neuroendocrine neoplasm: Compared with patients who received upfront PRRT, those who received upfront chemotherapy or targeted therapy more frequently had neuroendocrine tumors of pancreatic origin (137 patients [76.5%] vs 123 [37.4%]; P < .001), functioning tumors (137 [76.5%] vs 208 [63.2%]; P = .008), grade 2 or 3 neuroendocrine tumors (123 [68.7%] vs 164 [49.8%]; P < .001), and neuroendocrine tumors with a Ki-67 proliferation index greater than 10% (45 [25.2%] vs 33 [10.0%]; P < .001).